What do systematic reviews say?

Interferon vs no intervention

• Pharmacological interventions for acute hepatitis B infection 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

• Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 4981 participants
  Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).

• Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
  RR 1.12 [0.95, 1.3]
  4 studies · 3900 participants
  Low

Type I Interferons vs placebo

Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).

• Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.74 [0.13, 4.14]
  4 studies · 468 participants
  Low

Interferon beta‐1a vs placebo

Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).

• Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory… 2017 · Cochrane Headline outcomes only
  RR 4.5 [0.25, 80.05]
  1 study · 67 participants
  Low

Interferon beta‐1a vs placebo

It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

• Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 0.92 [0.23, 3.72]
  1 study · 19 participants
  Very low